मूलभूत आँकड़े
| LEI | 549300RWWOUFLHTY1224 |
| CIK | 1679363 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Morphic Holding, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| November 14, 2024 |
SC 13G/A 1 p24-3233sc13ga.htm MORPHIC HOLDING, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38940 MORPHIC HOLDING, INC. (Exact name of registrant as specified in i |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Pers |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizatio |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
EX-99.(a)(5)(B) Exhibit (a)(5)(B) Aug. 16, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-374-1878 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease Broadens Lilly’s immunology pipeline with Morphic’s oral integrin th |
|
| August 16, 2024 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MORPHIC HOLDING, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MORPHIC HOLDING, INC. 1. The name of the Corporation is: Morphic Holding, Inc. 2. The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is: National Registered Agents, Inc. 3. The nature of the |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Morphic Holding, Inc. (Name of Subject Company) Morphic Holding, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
AMENDED AND RESTATED BYLAWS MORPHIC HOLDING, INC. (a Delaware corporation) ARTICLE I Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MORPHIC HOLDING, INC. (a Delaware corporation) ARTICLE I STOCKHOLDERS Section 1. Annual Meetings. The annual meeting of the stockholders of Morphic Holding, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time, within or w |
|
| August 7, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Morphic Holding, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) |
|
| August 7, 2024 |
MORF / Morphic Holding, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Morphic Holding, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61775R105 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (ident |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Morphic Holding, Inc. (Name of Subject Company) Morphic Holding, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) |
|
| August 1, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Pers |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Morphic Holding, Inc. (Name of Subject Company) Morphic Holding, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| July 19, 2024 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 19, 2024 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of MORPHIC HOLDING, INC. |
|
| July 19, 2024 |
Summary Advertisement, as published in The Wall Street Journal on July 19, 2024. Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| July 19, 2024 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of MORPHIC HOLDING, INC. |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as o |
|
| July 19, 2024 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of MORPHIC HOLDING, INC. |
|
| July 19, 2024 |
Exhibit (d)(8) THIRD AMENDMENT TO MUTUAL CONFIDENTIALITY AGREEMENT Eli Lilly and Company and Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Exhibit (d)(7) SECOND AMENDMENT TO MUTUAL CONFIDENTIALITY AGREEMENT Eli Lilly and Company and Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Exhibit (d)(6) FIRST AMENDMENT TO CONFIDENTIALITY AGREEMENT Eli Lilly and Company and Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Exhibit (d)(9) FOURTH AMENDMENT TO MUTUAL CONFIDENTIALITY AGREEMENT Eli Lilly and Company and Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issuer or other person)) Table 1-Transaction Valuation Transaction Valuation* Fee rate Amount of Filing Fee** F |
|
| July 19, 2024 |
Exhibit (d)(5) MUTUAL AGREEMENT OF CONFIDENTIALITY This Mutual Agreement of Confidentiality (this “Agreement”) dated as of the last date signed below (the “Effective Date”) is made by and between Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Offer to Purchase, dated July 19, 2024. Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of MORPHIC HOLDING, INC. |
|
| July 19, 2024 |
Exclusivity Agreement, dated June 25, 2024, between Eli Lilly and Company and Morphic Holding, Inc. Exhibit (d)(10) EXCLUSIVITY AGREEMENT This EXCLUSIVITY AGREEMENT (this “Agreement”) is effective as of June 25, 2024, by and between Morphic Holding, Inc. |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as o |
|
| July 8, 2024 |
Business Partner/Vendor Letter, dated July 8, 2024 (Exhibit 99.4) Exhibit 99.4 Dear [Valued Partner / INSERT CUSTOMARY GREETING], This morning, Morphic announced that it has entered into an agreement to be acquired by Eli Lilly and Company (“Lilly”), marking a new phase for our company and the potential for oral integrin medicines. You can read more about the announcement in our joint press release . Morphic believes – and has stated – that the patient impact of |
|
| July 8, 2024 |
Exhibit 99.1 July 8, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Chris Erdman; [email protected]; 617-686-1718 (Morphic) Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease Acquisition to expand Lilly’s immunology pipeline w |
|
| July 8, 2024 |
Advocacy Group/Clinical Advisor Letter, dated July 8, 2024 (Exhibit 99.5) Exhibit 99.5 Dear [Valued Partner / INSERT CUSTOMARY GREETING], This morning, Morphic announced that it has entered into an agreement to be acquired by Eli Lilly and Company (“Lilly”), marking a new phase for our company and the potential for oral integrin medicines. You can read more about the announcement in our joint press release . Morphic believes – and has stated – that the patient impact of |
|
| July 8, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of July 7, 2024, among ELI LILLY AND COMPANY, RAINIER ACQUISITION CORPORATION and MORPHIC HOLDING, INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 SECTION 1.01 Definitions 2 SECTION 1.02 Terms Defined Elsewhere 11 SECTION 1.03 Interpretation and Rules of Construction 12 ARTICLE II THE OFFER 13 SECTION 2.01 The Offer 13 SECTION 2.02 Company Acti |
|
| July 8, 2024 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Morphic Holding, Inc. (Name of Subject Company) Morphic Holding, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 |
|
| July 8, 2024 |
Exhibit 10.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 7, 2024, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the stockholders of Morphic Holding, Inc., a Delaware corporation ( |
|
| July 8, 2024 |
LinkedIn Post, dated July 8, 2024 (Exhibit 99.7) Exhibit 99.7 MORF LinkedIn Post The following information was first posted by Morphic Holding, Inc. (“Morphic”) on LinkedIn on July 8, 2024: Morphic today announced it has entered into an agreement to be acquired by Eli Lilly and Company (“Lilly”) in an all-cash transaction valued at approximately $3.2 billion. This exciting milestone marks a new phase for our company, and we eagerly anticipate th |
|
| July 8, 2024 |
Employee FAQ, dated July 8, 2024 (Exhibit 99.3) Exhibit 99.3 Employee FAQ 1. What was announced today? Eli Lilly and Company (“Lilly”) and Morphic Holding, Inc. (“Morphic”) announced an agreement for Lilly to acquire Morphic for $57.00 per share, representing a total equity value of approximately $3.2 billion. 2. Why does Lilly want to acquire Morphic? Lilly was looking for opportunities to expand the breadth of its immunology portfolio and bui |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) |
|
| July 8, 2024 |
Joint Press Release, dated July 8, 2024 (Exhibit 99.1) Exhibit 99.1 July 8, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Chris Erdman; [email protected]; 617-686-1718 (Morphic) Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease Acquisition to expand Lilly’s immunology pipeline w |
|
| July 8, 2024 |
MORF / Morphic Holding, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Morphic Holding, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61775R105 (CUSIP Number) June 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| July 8, 2024 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Morphic Holding, Inc. |
|
| July 8, 2024 |
Analyst/Investor Courtesy Letter, dated July 8, 2024 (Exhibit 99.6) Exhibit 99.6 Subject: Morphic Enters into Agreement to be Acquired by Lilly Dear NAME, This morning, we announced that we have entered into an agreement to be acquired by Eli Lilly and Company (“Lilly”) (NYSE: LLY), in an all-cash transaction valued at approximately $3.2 billion. Under the terms of the agreement, Morphic shareholders will receive $57.00 in cash for each share of Morphic they own. |
|
| July 8, 2024 |
Exhibit 10.3 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 7, 2024, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the stockholders of Morphic Holding, Inc., a Delaware corporation ( |
|
| July 8, 2024 |
Exhibit 99.1 July 8, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Chris Erdman; [email protected]; 617-686-1718 (Morphic) Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease Acquisition to expand Lilly’s immunology pipeline w |
|
| July 8, 2024 |
Employee Letter, dated July 8, 2024 (Exhibit 99.2) Exhibit 99.2 Dear Morphic Team, I’m writing to share a landmark milestone in Morphic’s journey. Moments ago, we announced that we have entered into an agreement to be acquired by Eli Lilly and Company (“Lilly”), marking a new phase for our company and the potential for oral integrin medicines. You can read the specifics of this announcement in the press release that we issued together with Lilly. |
|
| July 8, 2024 |
Exhibit 10.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 7, 2024, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the stockholders of Morphic Holding, Inc., a Delaware corporation ( |
|
| June 5, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) |
|
| May 3, 2024 |
MORF / Morphic Holding, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) April 23, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| April 26, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES 424(b)(5) (Form Type) Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par valu |
|
| April 26, 2024 |
As filed with the Securities and Exchange Commission on April 26, 2024 As filed with the Securities and Exchange Commission on April 26, 2024 Registration No. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| April 26, 2024 |
Exhibit 1.2 MORPHIC HOLDING, INC. $350,000,000 SALES AGREEMENT April 26, 2024 TD Securities (USA) LLC (dba TD Cowen) 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Morphic Holding, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1.Issuance and Sale of Shares. The Company agrees that, |
|
| April 26, 2024 |
Exhibit 4.4 MORPHIC HOLDING, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS. 1 1.2 OTHER DEFINITIONS. 5 1.3 INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 5 1.4 RULES OF CONSTRUCTION. 6 ARTICLE 2 THE SECURITIES 6 2.1 ISSUABLE IN SERIES. 6 2.2 ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES. 6 2.3 EXECUT |
|
| April 26, 2024 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] MORPHIC HOLDING, INC. [If applicable, insert - FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MAT |
|
| April 26, 2024 |
TABLE OF CONTENTS EXPLANATORY NOTE This filing is being made pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, solely to add the Calculation of Filing Fee table with respect to the Prospectus Supplement dated May 2, 2023 filed by Morphic Holding, Inc. |
|
| April 26, 2024 |
EXHIBIT 107.1 CALCULATION OF FILING FEE TABLES Form S-3ASR (Form Type) Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 25, 2024 |
Exhibit 10.1 SIXTH AMENDMENT OF LEASE THIS SIXTH AMENDMENT OF LEASE (this “Sixth Amendment”) is made as of March 29, 2024, by and between ARE-MA REGION NO. 110, LLC, a Delaware limited liability company (“Landlord”), and MORPHIC THERAPEUTIC, INC., a Delaware corporation (“Tenant”), formerly known as Morphic Rock Therapeutic, Inc. RECITALS A. Landlord (as successor-in-interest to Astrazeneca Pharma |
|
| April 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| April 25, 2024 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 -Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended fir |
|
| March 12, 2024 |
Delivering A New Generation Of Integrin Medicines March 2024 This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing clinical trials and related data, updates and results from Morphic’s clinical trials and the potential therapeutic benefits of MORF-057. |
|
| March 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| February 22, 2024 |
Exhibit 97.1 Morphic Holding, Inc. Compensation Recovery Policy (Adopted September 11, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives’ certain incentive-based compensation in the event of an accounting restatement resulting from material non |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| February 22, 2024 |
Exhibit 10.18 Morphic Holding, Inc. 2024 Equity Inducement Plan 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future perfor |
|
| February 22, 2024 |
Form of Stock Option Award Agreemen Exhibit 10.19 MORPHIC HOLDING, INC. 2024 EQUITY INDUCEMENT PLAN NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Morphic Holding, Inc. (the “Company”) 2024 Equity Inducement Plan (the “Plan”) will have the same meanings in this Notice of Stock Option Grant and the electronic representation of this Notice of Stock Option Grant established and maintained by the |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizat |
|
| February 22, 2024 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023 -Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- -GARNET phase 2 trial of MORF-057 in Crohn’s disease (CD) expected to begin enrolling in the first half of 2024- -Ended |
|
| February 22, 2024 |
EXHIBIT 107.1 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value |
|
| February 22, 2024 |
As filed with the Securities and Exchange Commission on February 22, 2024 As filed with the Securities and Exchange Commission on February 22, 2024 Registration No. |
|
| February 22, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Morphic Holding, Inc. Name of Subsidiary Jurisdiction Morphic Therapeutic, Inc. Delaware Morphic Security Corporation Massachusetts Morphic Therapeutic UK Ltd United Kingdom |
|
| February 22, 2024 |
Form of Restricted Stock Award Agreemen Exhibit 10.20 MORPHIC HOLDING, INC. 2024 EQUITY INDUCEMENT PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Unless otherwise defined herein, the terms defined in the Morphic Holding, Inc. (the “Company”) 2024 Equity Inducement Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of this Notice of Restricted Stock Unit Award establi |
|
| February 14, 2024 |
MORF / Morphic Holding, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 morf13ga4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 14, 2024 |
MORF / Morphic Holding, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 morf13ga4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 14, 2024 |
MORF / Morphic Holding, Inc. / Point72 Asset Management, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 9, 2024 |
MORF / Morphic Holding, Inc. / Polaris Partners VII, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d753706dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R |
|
| February 9, 2024 |
MORF / Morphic Holding, Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d732799dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 8, 2024 |
MORF / Morphic Holding, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Morphic Holding, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61775R105 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of (Commission (I.R.S. Employe |
|
| January 12, 2024 |
Exhibit 99.1 Excerpt of Transcript from the Question and Answer Session of a Morphic Holding, Inc. Public Presentation Held on January 10, 2024 Marc Schegerin: So, you know we have a [Form 10-]K in a few weeks, but I think it’s no surprise given our last [Form 10-]Q that we have approximately $700 million in the bank at the end of ’23 and that our guidance has been very consistent for the last yea |
|
| January 12, 2024 |
Delivering A New Generation Of Integrin Medicines January 2024 Exhibit 99.2 Delivering A New Generation Of Integrin Medicines January 2024 This presentation contains “forward - looking” statements within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing cl inical trials and related data, updates and results from Mo |
|
| January 3, 2024 |
Exhibit 99.1 Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference -Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 - Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Prav |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizatio |
|
| December 6, 2023 |
Exhibit 14.1 MORPHIC HOLDING, INC. CODE OF CONDUCT AND ETHICS As adopted June 10, 2019 As Amended December 1, 2023 I.INTRODUCTION Morphic Holding, Inc., a Delaware corporation (collectively with its subsidiaries, the “Company”) has adopted this Code of Conduct and Ethics (this “Code”) to set high standards of ethical business conduct and provide guidance applicable to every Covered Person (as defi |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| November 3, 2023 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023 -Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and ma |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| October 18, 2023 |
Purchase Agreement, dated May 21, 2021, by and among TAS and the Polaris Entities. EX-99.1 2 ea186879ex99-1morphic.htm PURCHASE AGREEMENT, DATED MAY 21, 2021, BY AND AMONG TAS AND THE POLARIS ENTITIES Exhibit 99.1 Execution Version PURCHASE AGREEMENT This PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 21, 2021 (the “Trade Date”) by and among each of the entities listed in Exhibit A attached hereto (each a “Seller” and collectively, the “Sellers”), and T |
|
| October 18, 2023 |
MORF / Morphic Holding Inc / SPRINGER TIMOTHY A - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Morphic Holding, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 61775R105 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mullins Riley & Scarborough LLP 101 Constitution Avenue NW, Suite 900 Washington, DC 2 |
|
| October 18, 2023 |
EX-99.4 3 ea186879ex99-4morphic.htm JOINT FILING AGREEMENT Exhibit 99.4 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of October 18, 2023, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership by each of the und |
|
| October 12, 2023 |
EMERALD-1 Full Data Presentation October 12, 2023 This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing clinical trials and related data, updates and results from Morphic’s clinical trials and the potential therapeutic benefits of MORF-057. |
|
| October 12, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| October 2, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| October 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) September 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| September 26, 2023 |
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence Exhibit 99.1 Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) – Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Tipirneni is expected to return to his role as Chief Exe |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organiza |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| August 3, 2023 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 -Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater than $730 million in cash and equivalents at 6/30/23; extended cash runway into second half of 2027 - - |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| August 3, 2023 |
Restated Certificate of Incorporation, as amended Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF MORPHIC HOLDING, INC. Morphic Holding, Inc. (hereinafter called the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1.That the name of this Corporation is Morphic Holding, I |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) |
|
| May 4, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-258703 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 11, 2021) 5,333,334 Shares Common Stock We are offering 5,333,334 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is quoted on The Nasdaq Global Market under the symbol “MORF.” On May 2, 2023, the last |
|
| May 3, 2023 |
Morphic Therapeutic Announces Proposed Public Offering Exhibit 99.1 Morphic Therapeutic Announces Proposed Public Offering WALTHAM, Mass., May 2, 2023 (GLOBE NEWSWIRE) - Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering of its common stock. In addition, Morphic intends to grant the und |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of (Commission (I.R.S. Employer inc |
|
| May 3, 2023 |
Underwriting Agreement dated May 2, 2023 EX-1.1 2 tm2314474d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 5,333,334 Shares Morphic Holding, Inc. UNDERWRITING AGREEMENT May 2, 2023 JEFFERIES LLC COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Morphic Holding, |
|
| May 3, 2023 |
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering Exhibit 99.2 Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering WALTHAM, Mass., May 3, 2023 (GLOBE NEWSWIRE) – Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an underwritten public offering of 5,333,334 shares of its common stock at |
|
| May 2, 2023 |
424B5 1 tm2313471-1424b5.htm 424B5 TABLE OF CONTENTS This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell th |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| April 25, 2023 |
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023 Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023 -In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal observed - -EMERALD-2 Phase 2b Trial of MORF-057 progressing on track- -Ended first q |
|
| April 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of (Commission (I.R.S. Employer |
|
| April 25, 2023 |
EMERALD - 1 Topline Data April 25, 2023 Exhibit 99.1 EMERALD - 1 Topline Data April 25, 2023 Forward Looking Statements This presentation contains “forward - looking” statements within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing cl inical trials and related data, updates and results fro |
|
| April 21, 2023 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 10, 2023 |
Preliminary Proxy Statement on Schedule 14A, filed with the SEC on April 10, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizat |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| February 23, 2023 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022 -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis- -Ended 2022 with $348 million in cash and equivalents; ~$100 million from February priv |
|
| February 23, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Morphic Holding, Inc. Name of Subsidiary Jurisdiction Morphic Therapeutic, Inc. Delaware Morphic Security Corporation Massachusetts Morphic Therapeutic UK Ltd United Kingdom |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
EXHIBIT 107.1 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
EXHIBIT 107.1 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value |
|
| February 13, 2023 |
EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, $0.0001 par value per share, of Morphic Holding, Inc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 193 |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of (Commission (I.R.S. Employ |
|
| February 13, 2023 |
MORF / Morphic Holding Inc / Artal International S.C.A. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) September 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 13, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Morphic Holding, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of the date hereof (the “Purchase Agreement”). Capita |
|
| February 13, 2023 |
Exhibit 3.1 MORPHIC HOLDING, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS As Amended and Restated on February 12, 2023 MORPHIC HOLDING, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Article I: STOCKHOLDERS 1 Section 1.1: Annual Meetings 1 Section 1.2: Special Meetings 1 Section 1.3: Notice of Meetings 1 Section 1.4: Adjournments 1 Section 1.5: Quorum 2 Se |
|
| February 13, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Morphic Holding, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS WHEREAS, the Company and the Investors are executing and |
|
| February 13, 2023 |
EX-4.1 3 tm236505d1ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT T |
|
| January 20, 2023 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| November 2, 2022 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022 Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter WALTHAM, Mass. – November 2, 2022 – Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company devel |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| October 24, 2022 |
Exhibit 99.1 Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible WALTHAM, Mass. ? October 24, 2022 ? Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapie |
|
| October 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| August 3, 2022 |
Amended and Restated 2019 Equity Incentive Plan Exhibit 10.1 Morphic Holding, Inc. Amended and Restated 2019 Equity Incentive Plan 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to parti |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| August 3, 2022 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022 Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team Ended second quarter 2022 with $397.6 million in cash and equivalents Cash runway extended into second half of 2025 WALTHAM, Mass. – Augus |
|
| June 21, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) |
|
| May 12, 2022 |
Exhibit 99.1 Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer WALTHAM, Mass. ? May 12, 2022 ? Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced two key executive appointments. Dr. Bruce Rogers has been named P |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) ( |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| May 4, 2022 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022 Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Described new understanding of ?4?7-expressing immune cells and MORF-057 dose response in oral presentation at ECCO 2022 Announced key appointments and advancements in leadership team Ended first quarter 2022 with $3 |
|
| April 29, 2022 |
DEF 14A 1 morfdef14a-2022.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizat |
|
| February 24, 2022 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Morphic Holding, Inc. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| February 24, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Morphic Holding, Inc. Name of Subsidiary Jurisdiction Morphic Therapeutic, Inc. Delaware Morphic Security Corporation Massachusetts |
|
| February 24, 2022 |
Form of Change in Control and Severance Agreement Exhibit 10.19 Change in Control and Severance Agreement This Change in Control and Severance Agreement (the ?Agreement?) is entered into by and between [ ] (the ?Executive?) and Morphic Holding, Inc., a Delaware corporation (the ?Company?)1, and is effective as of the Effective Date. 1.Term of the Agreement. This Agreement shall terminate upon the date the Executive?s employment with the Company t |
|
| February 24, 2022 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021 Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis scheduled to begin 1Q22; Phase 2b to commence mid-year Presented preclinical data from ?v?8 program at AACR and SITC demonstrating anti-tumor activity in checkpoint refractory cancer models Appointed Susanna |
|
| February 22, 2022 |
MORF / Morphic Holding Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A 1 d293266dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK- |
|
| February 14, 2022 |
MORF / Morphic Holding Inc / Omega Fund V, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 2)* Morphic Holding, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2021 (Date of Event Which Require |
|
| February 14, 2022 |
MORF / Morphic Holding Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 14, 2022 |
CUSIP No. 61775R105 13 G Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Morphic Holding, Inc. Dated: February 14, 2022 OMEGA FUND V, L.P. BY: Ome |
|
| February 14, 2022 |
CUSIP No. 38341P102 13G Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person?s true and lawful attorney-in-fact, to: (1) execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments thereto (collectively, the ?Reports?), |
|
| February 11, 2022 |
MORF / Morphic Holding Inc / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 3) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 11, 2022 |
MORF / Morphic Holding Inc / Polaris Partners VII, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2021 (D |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| November 4, 2021 |
Exhibit 10.1 FIFTH AMENDMENT OF LEASE THIS FIFTH AMENDMENT OF LEASE (the ?Amendment?) is made and entered into as of August 17, 2021 (the ?Amendment Effective Date?) by and between ASTRAZENECA PHARMACEUTICALS LP (?Landlord?) and MORPHIC THERAPEUTIC, INC. (f/k/a Morphic Rock Therapeutic, Inc., ?Tenant?). RECITALS A.Landlord and Tenant are parties to that certain Lease dated as of August 5, 2015 (th |
|
| November 4, 2021 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22 Announced Appointment of Nisha Nanda, Ph.D., to Morphic Board of Directors WALTHAM, Mass. ? Nov. 4, 2021 ? Morphic Therapeutic (Nasdaq: MORF), a biotech |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| November 1, 2021 |
MORF / Morphic Holding Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. |
|
| August 23, 2021 |
Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors WALTHAM, Mass., August 23, 2021 ? Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda currently serves as t |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizatio |
|
| August 13, 2021 |
Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham, Massachusetts 02451 Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham, Massachusetts 02451 August 13, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Deanna Virginio Re: Morphic Holding, Inc. Registration Statement on Form S-3 filed on August 4, 2021 (File No. 333-258435) Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended, Morphic |
|
| August 12, 2021 |
MORF / Morphic Holding Inc / Novo Holdings A/S - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy, |
|
| August 11, 2021 |
Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham, Massachusetts 02451 Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham, Massachusetts 02451 August 11, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Deanna Virginio Re: Morphic Holding, Inc. Registration Statement on Form S-3 filed on August 4, 2021 (File No. 333-258435) Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended, Morphic |
|
| August 11, 2021 |
, dated July 1, 2020, by and between the Registrant and Jefferies LLC, as amended on August 1 Exhibit 1.3 AMENDED AND RESTATED AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM August 11, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This amended and restated Amendment No. 1 to the Open Market Sale AgreementSM (this ?Amendment?), which amends and restates the amendment No. 1 to the Open Market Sale Agreementsm dated as of August 4, 2021 (the ?Origin |
|
| August 11, 2021 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] MORPHIC HOLDING, INC. [If applicable, insert?-?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS ????% OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS ????% OF ITS PRINCIPAL AMOUNT, THE YIEL |
|
| August 11, 2021 |
As filed with the Securities and Exchange Commission on August 11, 2021 As filed with the Securities and Exchange Commission on August 11, 2021 Registration No. |
|
| August 11, 2021 |
Exhibit 4.4 MORPHIC HOLDING, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS. 1 1.2 OTHER DEFINITIONS. 5 1.3 INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 5 1.4 RULES OF CONSTRUCTION. 6 ARTICLE 2 THE SECURITIES 6 2.1 ISSUABLE IN SERIES. 6 2.2 ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES. 6 2.3 EXECUT |
|
| August 4, 2021 |
Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K UNDER THE SECURITIES ACT OF 1933, AS AMENDED, BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AMENDMENT NO. 2 TO RESEARCH COLLABORATION AND OPTION AGREEMENT This Amendment No. 2 to Research C |
|
| August 4, 2021 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] MORPHIC HOLDING, INC. [If applicable, insert?-?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS ????% OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS ????% OF ITS PRINCIPAL AMOUNT, THE YIEL |
|
| August 4, 2021 |
As filed with the Securities and Exchange Commission on August 4, 2021 As filed with the Securities and Exchange Commission on August 4, 2021 Registration No. |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| August 4, 2021 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22 Presented positive preclinical data from ?v?8 program at AACR Annual Meeting demonstrating anti-tumor activity in checkpoint refractory cancer models Announced Appointment o |
|
| August 4, 2021 |
Exhibit 4.4 MORPHIC HOLDING, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS. 1 1.2 OTHER DEFINITIONS. 5 1.3 INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 5 1.4 RULES OF CONSTRUCTION. 6 ARTICLE 2 THE SECURITIES 6 2.1 ISSUABLE IN SERIES. 6 2.2 ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES. 6 2.3 EXECUT |
|
| August 4, 2021 |
, dated July 1, 2020, by and between the Registrant and Jefferies LLC, as amended on August 4, 2021 Exhibit 1.3 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM August 4, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this ?Amendment?) is entered into as of the date first written above by Morphic Holding, Inc., a Delaware corporation (the ?Company?), and Jefferies LLC (?Agent?), that are parties to |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| July 9, 2021 |
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD MORF-057 well tolerated across all phase 1 cohorts Dose-dependent ?4?7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset migration and CCR9 transcript levels provide early proof of biology Conference call today at 8:00 AM ET WALTHAM, Mass. |
|
| July 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2021 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization) |
|
| June 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of (Commission (I.R.S. Employer in |
|
| June 1, 2021 |
Exhibit 99.1 Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO?21 Virtual Congress May 28, 2021 Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study confirmed |
|
| May 17, 2021 |
10-Q/A 1 morphic-10xqaq12021.htm 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti |
|
| April 30, 2021 |
DEFA14A 1 morfdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e) |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organization |
|
| April 29, 2021 |
Exhibit 99.1 Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to present full MORF-057 Phase 1 data set at the ECCO?21 Virtual Congress in July Completed $245 million upsized pub |
|
| April 29, 2021 |
filed with the SEC on April 29, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) ? Definitive Proxy Statement |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| April 29, 2021 |
Exhibit 10.2 Change in Control and Severance Agreement This Change in Control and Severance Agreement (the ?Agreement?) is entered into by and between Peter Linde (the ?Executive?) and Morphic Holding, Inc., a Delaware corporation (the ?Company?) 1, and is effective as of the Effective Date. 1.Term of Agreement. (a)The term of this Agreement shall terminate upon the earlier of the third (3rd) anni |
|
| April 29, 2021 |
Offer Letter, dated February 20, 2020, by and between the Registrant and Peter Linde. Exhibit 10.1 February 6, 2020 Dear Peter: I am very pleased to extend an offer to join Morphic Holding, Inc. (the ?Company?) on the following terms and conditions: 1. Position. You will become the Chief Medical Officer, reporting to Praveen Tipirneni, President and Chief Executive Officer of the Company. 2. Start Date. Your start date is expected to occur on March 16, 2020. Your actual start date |
|
| April 29, 2021 |
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors -Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term- Waltham, MA, April 28, 2021 - Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its Board of Directors. |
|
| March 11, 2021 |
Amendment No. 1 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6 |
|
| March 3, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 MORPHIC HOLDING, INC. (Exact name of registrant as specified in its charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| March 3, 2021 |
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering Exhibit 99.1 Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering WALTHAM, Mass., March 2, 2021 (GLOBE NEWSWIRE) – Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares |
|
| March 3, 2021 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-239607? prospectus supplement (To prospectus dated July 8, 2020) 3,500,000 Shares? Common Stock? We are offering 3,500,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is quoted on The Nasdaq Global Market under the symbol ?MORF.? On March 2, 2021, the la |
|
| March 3, 2021 |
Underwriting Agreement dated March 2, 2021 Exhibit 1.1 3,500,000 Shares Morphic Holding, Inc. UNDERWRITING AGREEMENT March 2, 2021 JEFFERIES LLC COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Morphic Holding, Inc., a Delaware corporation (the ?Compa |
|
| March 1, 2021 |
TABLE OF CONTENTS This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this prospectus supplement is not complete and may be changed. |
|
| March 1, 2021 |
Exhibit 10.19 ? ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. ? AMENDMENT NO. 1 TO RESEARCH COLLABORATION AND OPTION AGREEMENT ? This Amendment No. 1 to Research Collaboration and Option Agreement (this ?First Amendment?) is dated as of Decembe |
|
| March 1, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 1, 2021 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED ? General Our authorized capital stock consists of 400,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value per share. The following description summarizes the most important terms of our c |
|
| March 1, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 ? Subsidiaries of Morphic Holding, Inc. ? ? ? ? Name of Subsidiary ? Jurisdiction ? ? ? Morphic Therapeutic, Inc. ? Delaware Morphic Security Corporation ? Massachusetts ? |
|
| March 1, 2021 |
As filed with the Securities and Exchange Commission on March 1, 2021 Registration No. |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 ? Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) ? ? ? Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation |
|
| March 1, 2021 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020 Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 AbbVie exercised license option to αvβ6 integrin inhibitor program for fibrotic diseases Expanded research and development collaboration with Janssen through third integrin program Conference call today at 8:00 a.m. ET W |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2021 |
Exhibit 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, par value $0. |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 12, 2021 |
EX-99.1 CUSIP No. 61775R105 13G Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Morphic Holding, Inc. Dated: February 12, 2021 OMEGA FUND V, L.P. |
|
| February 12, 2021 |
CUSIP No. 61775R105 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: February 12, 2021 PFIZER INC. By: /s/ Su |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Morphic Holding, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2020 (Date of Event Which Require |
|
| February 12, 2021 |
EX-99.2 3 d131911dex992.htm EX-99.2 CUSIP No. 38341P102 13G Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person’s true and lawful attorney-in-fact, to: (1) execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments the |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION CUSIP No. 617755R105 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1 )1 Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 617755R105 (CUSIP Nu |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Morphic Holding, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61775R105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of (Commission (I.R.S. Employer |
|
| December 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| December 4, 2020 |
Exhibit 99.1 Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors WALTHAM, Mass. – December 4, 2020 – Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W. Edwards, to its Board of Directors. Dr. Edwards is a veteran leader in the drug development industry, r |
|
| November 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizati |
|
| November 9, 2020 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results Initiated phase 1 clinical trial for MORF-057 with results expected by mid-2021 Presented data at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057 Received $20 million from AbbVie exercising option to αvβ6 integrin inhibitor program WALTHAM, Mass. – November 9, 2020 – Morphic |
|
| September 23, 2020 |
DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES October 2020 Exhibit 99.1 DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES October 2020 Forward Looking Statements This presentation contains “forward - looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic’s or our partners’ plans to develop and commercialize oral small - molecule integrin therape |
|
| September 23, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 MORPHIC HOLDING, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) Delaware 001-38940 47-3878772 ( |
|
| August 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2020 MORPHIC HOLDING, INC. (Exact name of registrant as specified in its charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of Incorporation) (Commission F |
|
| August 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13, OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| August 10, 2020 |
Offer Letter, dated February 3, 2020, by and between Marc Schegerin, and Morphic Holding, Inc. Exhibit 10.1 January 29, 2020 Dear Marc: I am very pleased to extend an offer to join Morphic Holding, Inc. (the “Company”)1 on the following terms and conditions: 1. Position. You will become the Chief Financial Officer and Chief Operating Officer, reporting to Praveen Tipirneni, President and Chief Executive Officer of the Company. 2. Start Date. Your start date is expected to occur on April 13, |
|
| August 10, 2020 |
Exhibit 10.2 CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is entered into by and between Marc Schegerin, M.D. (the “Executive”) and Morphic Holding, Inc., a Delaware corporation (the “Company”) 1, and is effective as of the Effective Date. 1. Term of Agreement. (a) The term of this Agreement shall terminate upon the earlier of the third |
|
| August 10, 2020 |
Exhibit 99.1 Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results Company’s first IND accepted by FDA for MORF-057 in IBD phase 1 study expected to begin in third-quarter 2020 Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM, Mass. – August 10, 2020 – Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 Morphic Holding, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38940 47-3878772 (State or other jurisdiction of incorporation or organizatio |
|
| July 6, 2020 |
MORPHIC HOLDING, INC. 35 Gatehouse Drive, A2 Waltham, MA 02451 July 6, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Morphic Holding, Inc. Registration Statement on Form S-3 Filed July 1, 2020 File No. 333-239607 Requested Date: July 8, 2020 Requested Time: 4:00 p.m. Eastern Time |
|
| July 1, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 1, 2020 Registration No. |
